GSK suspends sale of antacid Zinetac after USFDA issues advisory

A day after the Drug Controller General of India (DCGI) asked the state Food and Drug Administrations (FDAs) to verify the bulk drug and formulation (medicine) of ranitidine made by manufacturers in their jurisdiction, British multinational drug major GlaxoSmithKline Pharmaceuticals suspended the distribution and supply of ranitidine to all markets, including India as a precautionary measure. Other Indian drugmakers have also started testing their ranitidine products at various laboratories after the US FDA issued an advisory on the drug to health care professionals.
 
In India, the drug is sold as one of the most popular ranitidine brands, Zinetac, which